Company Overview and News

7
Magnitude 6.1 quake in Japan's Osaka area kills three, stops factories

2018-06-18 theedgemarkets
TOKYO (June 18): A magnitude 6.1 earthquake shook Osaka, Japan's second-biggest metropolis, early on Monday, killing three people, halting factory lines in an industrial area and bursting water mains, government and company officials said.
DKILY TM TYT TOYOF HHPG DKILF HHPD MMTOY 7203 KUBTY 6367 7211 MMTOF

7
Osaka earthquake causes auto and electronics plants to suspend operations

2018-06-18 japantimes.co.jp
OSAKA – A powerful earthquake that hit Osaka and surrounding areas on Monday affected a number of large businesses, forcing Honda Motor Co., Panasonic Corp. and other well-known manufacturers to suspend production and retailers to close.
DKILF PCRFY DKILY MMTOY TM 7203 TYT 6367 TOYOF 7211 MMTOF

5
Deaths feared, plants and trains halted after Osaka quake

2018-06-18 theedgemarkets
TOKYO (June 18): Several people were feared dead after a strong earthquake hit Osaka on Monday morning, rattling one of Japan’s industrial heartlands and halting trains and factories across the region.
PCRFY MMTOY TM 7203 TYT TOYOF 7211 MMTOF

2
Carlos Ghosn’s biggest test yet: how to untie the Renault-Nissan-Mitsubishi knot in the tech age

2018-06-16 scmp
The automotive world’s turnaround wunderkind and globalist par excellence says the industry’s future lies in services that combine technology and engines with applications
MMTOY GM.WS.A GM.WS.B GM.WS.C GM GM.WSB 7211 MMTOF

1
Ghosn Faces Investor Showdown on $9 Million Renault Pay - Bloomberg

2018-06-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
VLKAF MMTOY 7211 MMTOF

3
Japan firms to introduce electric vehicles in PH

2018-06-14 business.inquirer.net
Global auto giants Nissan and Mitsubishi are making a push to introduce their electric vehicles in the Philippines as efforts to promote the local market fall into place, according to an industry group.
MER MMTOY 7211 MMTOF

0
Malaysia PM floats new national car project

2018-06-11 channelnewsasia
TOKYO: Malaysia's newly-elected Prime Minister Mahathir Mohamad on Monday (Jun 11) floated the possibility of a national car project, despite the problems of a similar endeavour started during his previous term decades ago.
MMTOY 7211 MMTOF

0
Malaysia looks to Japan

2018-06-11 theedgemarkets
KUALA LUMPUR: The government’s fight against corruption, led by Prime Minister Tun Dr Mahathir Mohamad, is expected to lead to an improved business environment with heightened transparency, and Japanese investors are already taking notice, said the Japan External Trade Organisation’s (Jetro) Malaysian office managing director Akira Kajita.
MMTOY KMGGF 7211 MMTOF

17
Box (BOX) CEO Aaron Levie on Q1 2019 Results - Earnings Call Transcript

2018-05-31 seekingalpha
Good afternoon. My name is Christine and I will be your conference operator today. At this time, I would like to welcome everyone to the Box First Quarter Fiscal 2019 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Alice Lopatto, Head of Investor Relations, you may begin your conference.
STI.WS.B STI.WS.A MS.PRE MS.PRF MS.PRG MS.PRA MMTOY STI MS.PRI MS.PRK STI-A STI.PRE MS 7211 MMTOF

6
Nissan to cut North American production by up to 20% - Nikkei Asian Review

2018-05-29 asia.nikkei
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
MMTOY GM.WS.A TM GM.WS.B GM.WS.C 7203 TYT GM GM.WSB TOYOF 7211 MMTOF

10
Toyota touts free trade in opposition to U.S. auto tariffs

2018-05-27 japantimes.co.jp
Toyota Motor Corp. said Thursday it is opposed to the U.S. move to raise tariffs on imported vehicles, which could hit the domestic auto industry and economy.
7261 MZDAY TM TYT TOYOF VLKAF MMTOY GM.WS.A GM.WS.B MZDAF GM.WS.C 7203 GM 500570 GM.WSB TATAMOTORS 7211 MMTOF TTM

0
Renault-Nissan-Mitsubishi VC invests first $50 million in startups

2018-05-22 reuters
TEL AVIV (Reuters) - The Renault-Nissan-Mitsubishi alliance’s new venture capital fund has agreed five investments in four months totaling $50 million and will present another to its supervisory board next week, the fund’s head said.
MMTOY RNO 7211 MMTOF

0
Nissan is said to seek better terms in Renault merger talks

2018-05-18 livemint
Southfield: As Japan’s Nissan Motor Co. and Renault SA of France discuss ways—including a possible merger—to strengthen their ties, Nissan is resisting a combination unless the company gains more clout in key areas, according to people with knowledge of the matter.
MMTOY RNO 7211 MMTOF

0
Nissan Seeks Better Terms in Renault Merger Talks - Bloomberg

2018-05-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MMTOY RNO 7211 MMTOF

56
Electric-Car Era Threatens Firefighters With New Road Risks - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MMTOY BOE GM.WS.A GM.WS.B GM.WS.C GM GM.WSB BA 7211 MMTOF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...